An international collaboration to harmonize the quantitative plasma Epstein-Barr virus DNA assay for future biomarker-guided trials in nasopharyngeal carcinoma.
about
Comparison of Circulating Tumour Cells and Circulating Cell-Free Epstein-Barr Virus DNA in Patients with Nasopharyngeal Carcinoma Undergoing Radiotherapy.Different prognostic values of plasma Epstein-Barr virus DNA and maximal standardized uptake value of 18F-FDG PET/CT for nasopharyngeal carcinoma patients with recurrenceCan Epstein-Barr virus DNA load in nasopharyngeal brushings or whole blood predict recurrent nasopharyngeal carcinoma in a non-endemic region? A prospective nationwide study of the Dutch Head and Neck Oncology Cooperative Group.The clinical utility of plasma Epstein-Barr virus DNA assays in nasopharyngeal carcinoma: the dawn of a new era?: a systematic review and meta-analysis of 7836 casesA nomogram for predicting survival of nasopharyngeal carcinoma patients with metachronous metastasis.Prognostication of serial post-intensity-modulated radiation therapy undetectable plasma EBV DNA for nasopharyngeal carcinoma.Emerging biomarkers in head and neck cancer in the era of genomics.Plasma Epstein-Barr virus DNA as a biomarker for nasopharyngeal carcinoma.The role of Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma.Current State of PCR-Based Epstein-Barr Virus DNA Testing for Nasopharyngeal Cancer.ACR Appropriateness criteria® for nasopharyngeal carcinoma.Epigenetic markers for noninvasive early detection of nasopharyngeal carcinoma by methylation-sensitive high resolution melting.Circulating pre-treatment Epstein-Barr virus DNA as prognostic factor in locally-advanced nasopharyngeal cancer in a non-endemic area.Pretreatment hematologic markers as prognostic factors in patients with nasopharyngeal carcinoma: Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio.Clinical utility of plasma Epstein-Barr virus DNA and ERCC1 single nucleotide polymorphism in nasopharyngeal carcinoma.Epstein-Barr virus-targeted therapy in nasopharyngeal carcinoma.Prognostic nomogram for refining the prognostication of the proposed 8th edition of the AJCC/UICC staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapy.Prognostic value of plasma Epstein-Barr virus DNA level during posttreatment follow-up in the patients with nasopharyngeal carcinoma having undergone intensity-modulated radiotherapy.Revisiting induction chemotherapy before radiotherapy for head and neck cancer, part II: nasopharyngeal carcinoma.Chemokine CCL27 is a novel plasma biomarker for identification the nasopharyngeal carcinoma patients from the Epstein-Barr virus capsid antigen-specific IgA seropositive population.Individualizing treatment for patients with nasopharyngeal cancer.Inter-laboratory comparison of six real time polymerase chain reaction assays for detection of bovine leukemia virus proviral DNA.Pretreatment prognostic factors of survival and late toxicities for patients with nasopharyngeal carcinoma treated by simultaneous integrated boost intensity-modulated radiotherapy.Establishment and characterization of new tumor xenografts and cancer cell lines from EBV-positive nasopharyngeal carcinomaIntegrated genomic analyses in PDX model reveal a cyclin-dependent kinase inhibitor Palbociclib as a novel candidate drug for nasopharyngeal carcinoma
P2860
Q33685029-9D419357-773C-42C3-B8D4-D4A0B51EBD6DQ35326653-9FC63F45-1993-4BD7-87CD-02FC379DB3E7Q35619542-686A19AF-7135-4C6D-9135-49B90C38EC7CQ36152889-45BDAFD3-02D7-455D-87B0-E1F16468059EQ37327951-C295993C-FC2B-4D64-BDD8-7015E86459CBQ37706344-95E7186E-E532-4CCD-956C-D5722F79C39EQ38268896-2A1AD7A8-7F83-4378-B37A-EBB67B95374CQ38270678-BACFA4D8-F19B-493E-A3BB-B29DADAFC3CBQ38440804-A1E8668A-6220-423A-B560-0092E1378AE6Q38735125-176296F3-A112-4584-BDB3-8423D5DF8BD4Q38821590-6FE1E469-25D6-4D04-AA19-6EBC8C028D04Q38959017-21047155-79D8-4B66-AAB0-4CE4060038E2Q40179091-F5F8BE1E-DEAF-45D2-82B5-1B7E92C9F7A4Q40547023-4BAA6F7F-A2B8-4940-834A-A054F79AE425Q41758054-3B383AFE-E1E6-4B6B-9593-60B5E0CFB875Q42145376-AB0A5F56-A625-4BE2-9AEC-A22FD21FDBA8Q43292345-FF4E8E8B-5C81-4AC1-9C5E-2F580C06B886Q45325137-5122339B-EC4F-41BC-AEF7-D0256858F495Q46122963-523EF80F-16AD-4FE0-AE0F-D694C5D7C6A5Q47106227-BA6A8BD9-71D7-417E-BA80-A99C17DFD029Q51023342-1C65F36C-A6BA-4A4A-A455-C35CE94ACC7DQ54233019-4AB6F5D8-D799-44AC-BC18-FB1AE09EF8BEQ54253295-4B24B29E-8927-429E-8AAA-EB3173E38D92Q58599820-EB1669F1-3B68-4542-A015-F74DF3ED2A56Q58711257-7078B5E7-D0B9-4B73-8C09-85CA66FA0206
P2860
An international collaboration to harmonize the quantitative plasma Epstein-Barr virus DNA assay for future biomarker-guided trials in nasopharyngeal carcinoma.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
An international collaboration ...... s in nasopharyngeal carcinoma.
@ast
An international collaboration ...... s in nasopharyngeal carcinoma.
@en
type
label
An international collaboration ...... s in nasopharyngeal carcinoma.
@ast
An international collaboration ...... s in nasopharyngeal carcinoma.
@en
prefLabel
An international collaboration ...... s in nasopharyngeal carcinoma.
@ast
An international collaboration ...... s in nasopharyngeal carcinoma.
@en
P2093
P2860
P921
P1476
An international collaboration ...... s in nasopharyngeal carcinoma.
@en
P2093
Ann-Joy Cheng
Anthony T C Chan
Chun-Wei Wang
Hongbin Cao
Joseph T Chang
K C Allen Chan
K Kian Ang
Kuo-Chien Tsao
Qiang Zhang
P2860
P304
P356
10.1158/1078-0432.CCR-12-3702
P407
P577
2013-03-04T00:00:00Z